Rofecoxib

An NSAID that inhibits COX-2 activity with 1,000-fold selectivity over that of COX-1 (IC50s = 26 nM and &gt 50 &microM in human osteosarcoma cells) effective against pain and inflammation in various rodent models.

An NSAID that inhibits COX-2 activity with 1,000-fold selectivity over that of COX-1 (IC50s = 26 nM and &gt 50 &microM in human osteosarcoma cells) effective against pain and inflammation in various rodent models.

An NSAID that inhibits COX-2 activity with 1,000-fold selectivity over that of COX-1 (IC50s = 26 nM and &gt 50 &microM in human osteosarcoma cells) effective against pain and inflammation in various rodent models.

An NSAID that inhibits COX-2 activity with 1,000-fold selectivity over that of COX-1 (IC50s = 26 nM and &gt 50 &microM in human osteosarcoma cells) effective against pain and inflammation in various rodent models.

InformationRoflumilast (APTA 2217, B9302-107, BY 217, BYK 20869) is a selective inhibitor ofPDE4withIC50of 0.2-4.3 nM in a cell-free assay.In vitroRoflumilast displays anti-inflammatory and immunomodulatory in vitro. Roflumilast inhibits LTB4